{
  "section_id": "19",
  "frc_analysis_report": {
    "entity": {
      "phase_2_financial_analysis": {
        "enhanced_ratio_analysis": {
          "liquidity_ratios": {
            "current_ratio": {
              "2022": "0.003",
              "2021": "0.002",
              "trend": "Slightly improved but critically low",
              "benchmark_comparison": "Industry average: 1.5-2.0",
              "risk_assessment": "EXTREME - Company cannot meet short-term obligations"
            },
            "quick_ratio_acid_test": {
              "2022": "0.002 (excluding inventory)",
              "2021": "0.001",
              "calculation_notes": "(Cash + Receivables) / Current Liabilities",
              "implications": "Virtually no liquid assets",
              "investigation_points": ["Cash verification", "Receivables collectibility"]
            }
          },
          "efficiency_ratios": {
            "days_of_inventory": {
              "2022": "Cannot calculate (inventory not verifiable)",
              "2021": "Cannot calculate",
              "industry_comparison": "Hospital industry: 30-60 days",
              "operational_implications": "Unknown inventory management efficiency",
              "red_flags": ["Inventory cannot be verified", "No physical count records"]
            },
            "days_sales_outstanding": {
              "2022": "Cannot calculate (receivables not detailed)",
              "2021": "Cannot calculate",
              "credit_policy_assessment": "Not possible due to lack of data",
              "collection_issues": "Unknown - data insufficient"
            },
            "asset_turnover": {
              "2022": "0.84 (Revenue/Total Assets)",
              "2021": "0.55",
              "efficiency_assessment": "Improving but still below efficient levels",
              "capacity_utilization": "Potentially underutilized assets"
            }
          },
          "solvency_coverage_ratios": {
            "debt_to_equity": {
              "2022": "N/A (negative equity)",
              "2021": "N/A",
              "trend_analysis": "Consistently negative equity",
              "covenant_compliance_check": "Likely in default of loan covenants",
              "risk_level": "EXTREME"
            },
            "interest_coverage_ratio": {
              "2022": "-0.41 (EBIT/Interest)",
              "2021": "-0.75",
              "calculation": "(-836,920,348) / 2,058,397,838",
              "sustainability_assessment": "Unsustainable - operating losses cannot cover interest",
              "default_risk": "VERY HIGH"
            }
          },
          "profitability_ratios": {
            "return_on_assets_roa": {
              "2022": "-30.5%",
              "2021": "-49.7%",
              "analysis": "Improving but still deeply negative",
              "asset_utilization_assessment": "Assets generating significant losses"
            },
            "return_on_equity_roe": {
              "2022": "N/A (negative equity)",
              "2021": "N/A",
              "analysis": "Not meaningful due to negative equity",
              "shareholder_value_assessment": "Shareholders' investment completely eroded"
            },
            "net_profit_margin": {
              "2022": "-36.3%",
              "2021": "-91.1%",
              "trend": "Improving but still negative",
              "cost_structure_analysis": "High operating costs relative to revenue",
              "competitive_position": "Weak - unable to generate profits"
            }
          }
        }
      }
    }
  }
}